NCT01502202 - Intercalated Administration of PamCis With Gefitinib or Placebo as First Line Lung Adenocarcinoma in Never Smokers | Biotech Hunter

Enrollment

162

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

August 31, 2014

Study Completion Date

February 28, 2015

Conditions

Non Small Cell Lung CancerAdenocarcinoma

Interventions

DRUG

Gefitinib

Gefitinib 250mg, per PO. daily, D 5-18 (during 14 days)

DRUG

Placebo

Placebo 1 tablet, per PO, Daily on D 5-18 (during 14 days)

DRUG

Pemetrexed plusCIsplatin

Pemetrexed 500mg/m2 on D1 plus Cisplatin 75mg/m2 on D1 every 3 weeks maximum 9 cycles

Trial Locations (1)

RECRUITING

National Cancer Center, Goyang-si